title: High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.
abstract: Anaemia and iron deficiency are very common in inflammatory bowel disease. Clinical trials have shown intravenous iron to be effective and well tolerated. However, published experience in clinical practice with specific evaluation of the effect on quality of life is limited.
  
  
  
  We carried out a prospective, multicentre, observational study on the effects of ferric carboxymaltose in the treatment of iron deficiency anaemia in inflammatory bowel disease. Anaemia and iron deficiency were defined according to World Health Organization criteria. Efficacy and safety were evaluated at infusion, at 2 weeks and at 12 weeks. Quality of life was evaluated according to the SIBDQ-9 index. Complete response was defined as anaemia correction or more tan 2 g/dL increase in haemoglobin.
  
  
  
  A total of 88 courses of ferric carboxymaltose in 72 patients were evaluated. Complete response was observed in 46% of patients at week 2, and 81.2% at week 12. Quality of life improved significatively at week 2 in both complete responders and partial responders (p<0.0005); complete responders showed siginficantly better response (p=0.016). No predictive factor was identified. Only one transient adverse effect was observed; however, this was severe.
  
  
  
  Ferric carboxymaltose showed comparable efficacy to that demonstrated in clinical trials. After only two weeks of treatment, there was a significant improvement in quality of life, with a greater effect observed in those patients with a complete haematologic response. Intravenous iron can very quickly improve quality of life in inflammatory bowel disease.
authors.affiliation: Department of Gastroenterology, University Hospital "Miguel Servet", Zaragoza, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: García-López
authors.affiliation: Department of Gastroenterology, University Hospital "Miguel Servet", Zaragoza, Spain.
authors.forename: Judith Millastre
authors.initials: JM
authors.lastname: Bocos
authors.affiliation: Department of Gastroenterology, University Hospital "La Princesa", Institute of Health Investigation La Princesa (IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
authors.affiliation: Department of Gastroenterology, University Hospital "Miguel Servet", Zaragoza, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Bajador
authors.affiliation: Department of Gastroenterology, University Hospital "La Princesa", Institute of Health Investigation La Princesa (IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Chaparro
authors.affiliation: Department of Gastroenterology, University Hospital "La Princesa", Institute of Health Investigation La Princesa (IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Castaño
authors.affiliation: Department of Haematology and Haemotherapy, Hospital San Jorge, IdiPAZ-49 Aragon Institute of Health Institute, Huesca, Spain.
authors.forename: José A
authors.initials: JA
authors.lastname: García-Erce
authors.affiliation: Department of Gastroenterology, Hospital Clinic University "Lozano Blesa", IIS Aragón, CIBERehd, Zaragoza, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Gomollón
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D008297:Male; D008320:Maltose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D055815:Young Adult
chemical_list: D005290:Ferric Compounds; C522335:ferric carboxymaltose; D008320:Maltose